Figure 1｜Schematic representation of neuroprotective agents and known therapeutic targets for treatment of degenerative retinal disorders.
To date, several drugs, biologics and small molecules have been developed and tested for treatment of RD diseases. Figure 1 is a schematic diagram representing the main groups of neuroprotective agents and known corresponding molecular targets. Table 1 lists the neuroprotective agents that are under active or recently completed trials, registered on clinicaltrials.gov. These agents were categorized based on the mechanisms of drug action and disease targets, and the status of each clinical study is also described in Table 1. Notably, each class of agents may primarily target a specific pathway or have pleiotropic effects to enhance retinal neuron survival.